International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 550-555 doi: 10.5281/zenodo.16867907
Original Article
Serum Lactate Dehydrogenase Level as an Early Predictor of Morbidity in Neonates with Transient Tachypnea of the Newborn
 ,
 ,
 ,
Published
Aug. 13, 2025
Abstract

Background: Transient tachypnea of the newborn (TTNB) is a frequent cause of neonatal respiratory distress. Serum lactate dehydrogenase (LDH), a marker of cellular injury, may help predict disease severity and prognosis.

Objective: To evaluate serum LDH levels as an early predictor of morbidity in neonates with TTNB, defined by duration of NICU stay and incidence of complications.

Methods: A prospective observational study was conducted in the NICU at NIMS University Hospital, Jaipur, between May 2023 and October 2024. Neonates ≥34 weeks gestational age diagnosed with TTNB were included. Serum LDH was measured within 24 hours of admission. The correlation of LDH with NICU stay and complications was analysed using appropriate statistical tests.

Results: Among 140 neonates, 56.43% had elevated LDH (>750 IU/L). Elevated LDH was associated with prolonged NICU stay (8.15 ± 1.28 vs. 3.79 ± 1.32 days; p<0.0001) and higher complication rates (32.91% vs. 4.92%; p<0.0001). Strong correlation existed between LDH and NICU stay duration (r=0.8439), and moderate correlation with complications (r=0.4677).

Conclusion: Elevated serum LDH levels are associated with increased morbidity in neonates with TTNB. LDH may serve as a simple, early biochemical marker for risk stratification and prognostication in these patients. Further large-scale, multicentre studies are recommended to validate these findings

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
1002 Views
408 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved